Arch Therapeutics Inc (ARTH)

[Polyphemus]

AC5 has been commercial in US & Europe for almost 3 years & there has been no demand. AC5 is one of many products that accomplish the same results, though by different methods. Without a history of building revenues, AC5 is not a target for acquisition by a Strategic. Patents & technology have to produce a winner in the market for M&A event.. Symposia presentations in this case are meaningless window dressing & ARTH remains a zombie company.